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Abstract
Background: There is a lack of studies comparing the utility of C-reactive protein (CRP) with Procalcitonin (PCT) for
the management of patients with acute respiratory tract infections (ARI) in primary care. Our aim was to study the
correlation between these markers and to compare their predictive accuracy in regard to clinical outcome prediction.
Methods: This is a secondary analysis using clinical and biomarker data of 458 primary care patients with pneumonic
and non-pneumonic ARI. We used correlation statistics (spearman’s rank test) and multivariable regression models
to assess association of markers with adverse outcome, namely days with restricted activities and persistence of
discomfort from infection at day 14.
Results: At baseline, CRP and PCT did not correlate well in the overall population (r2 = 0.16) and particularly in
the subgroup of patients with non-pneumonic ARI (r2 = 0.08). Low correlation of biomarkers were also found
when comparing cut-off ranges, day seven levels or changes from baseline to day seven. High baseline levels of
CRP (>100 mg/dL, regression coefficient 1.6, 95 % CI 0.5 to 2.6, sociodemographic-adjusted model) as well as PCT
(>0.5ug/L regression coefficient 2.0, 95 % CI 0.0 to 4.0, sociodemographic-adjusted model) were significantly
associated with larger number of days with restricted activities. There were no associations of either biomarker
with persistence of discomfort at day 14.
Conclusions: CRP and PCT levels do not well correlate, but both have moderate prognostic accuracy in primary
care patients with ARI to predict clinical outcomes. The low correlation between the two biomarkers calls for
interventional research comparing these markers head to head in regard to their ability to guide antibiotic
decisions.
Trial registration: Current Controlled Trials, ISRCTN73182671
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Background
Acute respiratory tract infections (ARIs) are the most
common reason for antibiotic therapy in primary care
[1, 2]. Yet, about 70 % of ARIs are treated with antibi-
otics, despite their mainly viral etiology [3]. As a conse-
quence, antibiotic overuse results in increased antibiotic
resistance, antibiotic-induced adverse events, and costs
[4, 5]. A novel approach for more individualized and tar-
geted antibiotic therapy is the use of blood biomarkers,
such as C-reactive protein (CRP) or Procalcitonin (PCT)
[6–8]. Several trials in primary care have shown that the
use of one of these markers reduces antibiotic exposure, al-
though head to head comparison trials are currently lack-
ing [9–11]. A recent systematic search and meta-analysis
found a total of four observational studies from primary
care looking at CRP and PCT for their ability to predict
pneumonic infiltrate, need for hospitalization, and diagno-
sis of group A streptococcus pharyngitis [9]. Also, previous
observational studies compared the diagnostic perform-
ance of CRP and PCT in the hospital setting [12, 13] and
in septic patients in the ICU setting [14, 15]. However, a
comprehensive comparison analysis between these two
markers in the primary care setting is currently lacking.
Importantly, so far PCT protocols have been used mainly
for management of hospitalized and intensive care patients
due to the lack of high sensitive point of care tests (POCT).
Recently, a sensitive POCT has been developed and
may be increasingly used in primary care [16].
Herein, using data from a previous trial, our aim was
to study how well CRP and PCT correlate, and their pre-
dictive value for outcome discrimination in a large-scale
well-defined ARI cohort [17, 18].
Methods
Study design and setting
This predefined ancillary project included all patients
with upper and lower ARI enrolled between December
2004 and April 2006 into the PARTI trial (Procalcitonin-
guided antibiotic use versus a standard approach for
acute respiratory tract infections in primary care) [17].
Study details have been reported elsewhere [18]. In brief,
53 primary care physicians in northwest of Switzerland
consecutively screened adults with symptoms of an ARI
and, in their physician’s opinion in need of antibiotics,
were randomized to either a PCT-guided approach to
antibiotic therapy or to a standard approach where phy-
sicians were asked to adhere to current guidelines. The
primary non-inferiority outcome was the number of
days, during the first 14 days after baseline, where a pa-
tient’s activities were restricted by an ARI.
Selection of participants
All patients with the diagnosis of upper or lower RTI
and the physician’s intention to prescribe antibiotics,
based on evidence guidelines, were consecutively in-
cluded. Exclusion criteria were antibiotic use within the
previous 28 days, psychiatric disorders or inability to
give written informed consent, not being available for
follow-up, not being fluent in German, severe immuno-
suppression, cystic fibrosis, active tuberculosis, and the
need for immediate hospitalization.
Classification of patients was standardized according
to previously defined guidelines for the correct diagnosis
of patients with ARI [18]. For these subgroup analyses
we divided patients into three groups based on the initial
evaluation by a primary care physician: upper ARI com-
prised patients with rhinosinusitis, pharyngitis/tonsillitis,
and otitis media; lower non-pneumonic ARI comprised
patients with common cold, tracheo-bronchitis, influ-
enza, acute exacerbation of asthma or chronic obstruct-
ive pulmonary disease, and lower pneumonic ARI
comprised patients with community-acquired pneumo-
nia (CAP).
Biomarker measurement
Blood samples were collected from all recruited patients
on admission and day seven in ethylenediaminetetraace-
tic acid (EDTA) tubes. PCT determinations were made
using a centralized time-resolved amplified cryptate emis-
sion technology-based assay (Kryptor® PCT, Thermo Sci-
entific Biomarkers [B · R · A · H ·M · S AG], Hennigsdorf,
Germany) with a 0.06 μg/L functional sensitivity [19].
CRP concentrations were determined by an enzyme im-
munoassay having a detection limit <5 mg/dL (EMIT;
Merck Diagnostica, Zurich, Switzerland). For the purpose
of comparing cut-off ranges, PCT and CRP were strati-
fied in four corresponding groups each, namely for
PCT <0.1 μg/L, 0.1-0.25 μg/L, >0.25-0.5 μg/L and >0.5 μg/
L, and for CRP ≤20 mg/dL, 21–50 mg/dL, >51-99 mg/dL,
and ≥100 mg/dL, respectively, based on the use of these
markers in previous antibiotic stewardship trials in the
low acuity setting [2, 20, 21].
Outcomes
In line with the initial study protocol [18], the prede-
fined primary endpoint was the number of days, within
the first 14 days after baseline, during which a patient’s
daily activities (work or recreation) were restricted by a
respiratory tract infection. The secondary endpoint was
persistence of discomfort from infection at day 14. Both
endpoints were assessed by seven medical students,
blinded to the goal and design of the study, by conduct-
ing standardized follow-up interviews by telephone at 14
and 28 days after baseline.
Statistical analysis
We used descriptive statistics including mean with
standard deviation, median with interquartile range
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(IQR), and frequencies to describe the populations, as
appropriate.
Assessment of correlation between biomarkers was
performed by Spearman’s rank correlation analysis and
visualized with scatter-plots. We looked at correlations
between continuous biomarker levels and across cut-
off ranges as defined above. For biomarker kinetics, we
defined the change from baseline to day seven and
classified the relative change into 4 groups (decrease
of <25 %, 25–50 %, 50-75 % and >75 %).
To investigate associations between initial biomarker
levels and endpoints, we used linear and logistic regres-
sion analysis. We adjusted for sociodemographic charac-
teristics (age, gender, existence of comorbidities and
education level) and in a second model also for disease
severity (e.g. days spent with restricted activities before
randomization and antibiotic prescription). Analyses
were performed in the overall ARI patient population
and in subgroups of different ARI types (upper ARI,
non-pneumonic lower ARI, and pneumonic lower ARI).
We calculated sensitivity and specificity using different
clinically established cut-offs as defined above.
Statistical t-Tests were carried out at a 5 % significance
level. All statistical analyses were performed with STATA
Version 12.1 (Stata Corp, College Station, TX, USA).
Results
Patient population
This study included a total of 458 patients with a median
age of 45 years (60 % females). Forty percent (184 pa-
tients) had upper ARI, particularly acute rhinosinusitis
and acute pharyngitis/tonsillitis. Lower non-pneumonic
ARI was diagnosed in 45 % of patients with acute bron-
chitis being the pre-dominant diagnosis (28 %) and 15 %
had pneumonic lower RTI, namely CAP. Chest X-ray
was performed in 121 patients, in 23 % of non-
pneumonic ARI and in 97 % of CAP patients with non-
pneumonic and pneumonic LRTI. The median reported
degree of discomfort on recruitment was 6 – 7 (on a
scale of 0 – 10 with 0 meaning no discomfort at all).
Additional baseline characteristics of the study popula-
tion are summarized in Table 1.
Correlation between PCT and CRP in different ARIs
Figures 1 and 2 show correlations of CRP and PCT in
the overall population, and stratified by subgroups at
baseline and on day seven. At baseline, we found signifi-
cant correlations with however a low correlation coeffi-
cient between the two markers in the overall study
population (r2 = 0.16), as well as in all subgroups. High-
est correlations were found in the pneumonic lower ARI
group (r2 = 0.34). On day seven, there were again weak
correlations between both biomarkers in the overall
population as well as in the subgroups.
We also investigated correlation of markers across
well-established cut-off ranges (Tables 2 and 3). At base-
line, 42 % of patients were in similar cut-off ranges with
9 % of patients being in higher PCT ranges and 49 % in
higher CRP ranges. For day seven, 76 % of patients were
in similar cut-off ranges with 13 % of patients being in
higher PCT ranges and 11 % in higher CRP ranges.
Looking at kinetics found 11 % of patients had a similar
decrease in biomarker level with 75 % of patients having
a stronger CRP decrease and 9 % a stronger PCT de-
crease. An increase in biomarker level was observed in
5 % of patients.
Association of admission biomarker levels and adverse
outcome
Table 4 summarizes the results of regression analyses in-
vestigating the association of initial biomarker levels and
adverse outcomes, namely days with restricted activities
and persistence of ongoing discomfort at day 14. Analyses
were performed according to baseline and day seven




Age (years) – median [IQR] 45 (32–62)
Female gender – n (%) 273 (59.6 %)
Comorbidities
Presence of any comorbidity – n (%) 70 (15.3 %)
Finale diagnosis
Upper RTI 184 (40.2 %)
Acute rhinosinusitis – n (%) 104 (22.7 %)
Acute pharyngitis/tonsillitis – n (%) 75 (16.4 %)
Acute otitis media – n (%) 5 (1.1 %)
Lower non-pneumonic RTI 205 (44.8 %)
Common cold – n (%) 31 (6.8 %)
Acute bronchitis – n (%) 140 (30.6 %)
Influenza – n (%) 4 (0.9 %)
Exacerbated COPD – n (%) 21 (4.6 %)
Exacerbated asthma – n (%) 9 (2 %)
Lower pneumonic RTI 69 (15.1 %)
Medical outcome of patients
Days with restricted activities within
14 days – median [IQR]
9 (6–12)
Persisting discomfort after 14 days 208 (45.7 %)




CRP mg/dL median (SD) [IQR] 31 (60) (8.3-72.7)
PCT μg/L median (SD) [IQR] 0.08 (2.11) (0.05-0.11)
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biomarker levels. For CRP, we found levels >100 mg/dL to
be significantly associated with days of restricted activities
(coefficient: 1.6 (95 % CI: 0.5, 2.6), p = 0.005). For day
seven, results were similar with again levels >100 mg/dL
being significantly associated in sociodemographically ad-
justed analysis (coefficient: 3.3 (95 % CI: 0.5, 6.2), p =
0.022) and a trend in fully adjusted analysis. For PCT, only
initial levels >0.5ug/L were significantly associated with
days with restricted activities in sociodemographically ad-
justed analysis (coefficient 2.0, 95 % CI 0.0 to 4.0) with a
trend after full adjustment (p = 0.089).
We also repeated the same analysis in the different
subgroups, i.e. in patients with upper ARI and in lower
pneumonic and non-pneumonic ARI. While for the
upper ARI no significant associations were found, best
results were seen in the non-pneumonic lower ARI
group (see Additional files 1, 2, 3, 4 and 5).
Finally, we also investigated associations of biomarkers
with persistent discomfort after 14 days. For this end-
point, no significant associations were found for both
markers at baseline. For the day seven analysis, signifi-
cant results were found for CRP, but not PCT.
Discussion
The findings of this analysis including a large primary
care population with different types of ARI are threefold.
First, correlations between CRP and PCT levels were
low in the overall population and particularly in the
upper and non-pneumonic lower ARI. Second, high
levels of both markers in the highest cut-off range were
associated with days with restricted activity but not with
ongoing discomfort. Third, kinetics did not significantly
improve outcome prediction.
To date, ARI still represent an important public health
issue affecting millions of patients around the world. In-
correct or delayed diagnosis may directly lead to severe
complications and increases morbidity and mortality, es-
pecially in the inpatient setting [3]. Sputum and blood
cultures are commonly seen as the gold standard. Still,
these techniques have low sensitivity and lack practic-
ability (e.g. in case of non-productive cough) [22, 23].
Because differentiation of mild viral infection from more
severe infections is challenging, clinicians often start em-
piric antibiotic treatment which increases resistance of
common bacteria and causes drug-related side effects
[24, 25]. In this context, objectively measurable blood
biomarkers may help to assess severity and need for
more intensive treatment. There is still uncertainty
about optimal use of PCT or CRP in the primary care
setting for the management of patients. Herein, our ana-
lysis including a large and well defined cohort of ARI pa-
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Fig. 1 a-d: Correlation of Procalcitonin and CRP levels in lower and upper respiratory tract infections at baseline
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Compared to higher acuity settings, patients with low
acuity ARI had low PCT levels with minimal changes
over seven days. Yet, CRP levels showed a higher vari-
ability. This is also consistent with findings from other
primary care studies [26], suggesting that PCT is more
specific to bacterial infections and low in patients with
mainly viral infections, while CRP increases independ-




















All Patients (n=434) Day 7 










































LRTI non-pneu(n=199) Day 7





Fig. 2 a-c: Correlation of Procalcitonin and CRP levels in lower and upper respiratory tract infections on day 7
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Table 2 Classification of biomarkers at baseline and day seven
Baseline Overall (n = 450)
CRP < 20 CRP 20-50 CRP 50-100 CRP > 100 Total
PCT <0.1 141 82 62 15 300
47 % 27.3 % 20.7 % 5 % 100 %
PCT0.1-0.25 38 34 25 33 130
29.2 % 26.2 % 19.2 % 25.4 % 100 %
PCT 0.25-0.5 0 1 1 3 5
0 % 20 % 20 % 60 % 100 %
PCT > 0.5 1 0 0 14 15
6.7 % 0 % 0 % 93.3 % 100 %
Total 180 117 88 65 450
40 % 26 % 19.6 % 14.4 % 100 %
Day 7 Overall (n = 434)
CRP < 20 CRP 20-50 CRP 50-100 CRP > 100 Total
PCT <0.1 322 30 5 3 360
89.4 % 8.3 % 1.4 % 0.8 % 100 %
PCT0.1-0.25 52 7 6 3 68
76.5 % 10.3 % 8.8 % 4.4 % 100 %
PCT 0.25-0.5 2 1 0 0 3
66.7 % 33.3 % 0 % 0 % 100 %
PCT > 0.5 1 0 1 1 3
33.3 % 0 % 33.3 % 33.3 % 100 %
Total 377 38 12 7 434
86.9 % 8.8 % 2.8 % 1.6 % 100 %
Table 3 Classification of biomarkers at kinetics
Kinetics Overall (n = 428)
Increase (CRP) Decrease (CRP)
0 - 25 %
Decrease (CRP)






Increase (PCT) 22 14 17 26 53 132
16.7 % 10.6 % 12.9 % 19.7 % 40.2 % 100 %
Decrease (PCT) 0–25 % 8 6 9 10 51 84
9.5 % 7.1 % 10.7 % 11.9 % 60.7 % 100 %
Decrease (PCT) 25-50 % 6 5 7 17 60 95
6.3 % 5.3 % 7.4 % 17.9 % 63.2 % 100 %
Decrease (PCT) 50–75 % 2 2 5 9 66 84
2.4 % 2.4 % 6 % 10.7 % 78.6 % 100 %
Decrease (PCT) > 75 % 1 0 1 4 27 33
3 % 0 % 3 % 12.1 % 81.8 % 100 %
Total 39 27 39 66 257 428
9.1 % 6.3 % 9.1 % 15.4 % 60.1 % 100 %
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Table 4 Biomarker at baseline and day seven as predictor for days with restricted activities or persistence of discomfort after 14 days
Days with restricted activites: coefficient (95 % CI)
Demographic-adjusted model Fully adjusted modela Demographic-adjusted model Adjusteda
Biomarker at baseline CRP (mg/dL) 0.4 (−0.2 to 0.9), p = 0.169 0.3 (−0.3 to 0.9), p = 0.324 Biomarker on day 7 0.7 (0.1 to 1.4), p = 0.035 0.6 (−0.1 to 1.3), p = 0.075
CRP ≤20 Reference group Reference group Reference group Reference group
CRP 20-50 0.4 (−0.5 to 1.3), p = 0.37 0.4 (−0.5 to 1.3), p = 0.407 0.7 (−0.6 to 2.0), p = 0.264 0.8 (−0.5 to 2.1), p = 0.252
CRP 50-100 0.0 (−1.0 to 1.0), p = 0.956 −0.1 (−1.0 to 0.9), p = 0.920 2.5 (0.3 to 4.7), p = 0.024 2.4 (0.2 to 4.5), p = 0.035
CRP >100 1.6 (0.5 to 2.6), p = 0.005 1.4 (0.3 to 2.5), p = 0.014 3.3 (0.5 to 6.2), p = 0.022 2.7 (−0.3 to 5.7), p = 0.078
PCT (μg/L) 0.9 (0 to 1.9), p = 0.048 0.8 (−0.2 to 1.8), p = 0.123 0.7 (−0.6 to 2.1), p = 0.297 0.5 (−0.9 to 1.9), p = 0.484
PCT ≤0.1 Reference group Reference group Reference group Reference group
PCT 0.1-0.25 0.4 (−0.4 to 1.2), p = 0.320 0.3 (−0.5 to 1.1), p = 0.407 0.6 (−0.4 to 1.6), p = 0.249 0.5 (−0.5 to 1.5), p = 0.353
PCT 0.25-0.5 1.6 (−1.3 to 4.4), p = 0.288 1.2 (−1.8 to 4.1), p = 0.434 2.9 (−1.5 to 7.3), p = 0.194 2.3 (−2.1 to 6.7), p = 0.300
PCT >0.5 2.0 (0.0 to 4.0), p = 0.045 1.8 (−0.3 to 3.8), p = 0.089 −0.3 (−4.6 to 4.1), p = 0.900 −0.7 (−5.1 to 3.7), p = 0.751
Persistence of discomfort after 14 days: coefficient (95 % CI)
Demographic-adjusted model Adjusteda Demographic-adjusted model Adjusteda
Biomarker at baseline CRP (mg/dL) 1.0 (0.8 to 1.4), p = 0.831 1.0 (0.8 to 1.4), p = 0.828 Biomarker on day 7 1.7 (1.2 to 2.4), p = 0.005 1.7 (1.2 to 2.5), p = 0.005
CRP ≤20 Reference group Reference group Reference group Reference group
CRP 20-50 1.2 (0.7 to 1.9), p = 0.517 1.2 (0.7 to 2), p = 0.436 1.6 (0.8 to 3.2), p = 0.203 1.7 (0.8 to 3.4), p = 0.166
CRP 50-100 1.0 (0.6 to 1.8), p = 0.862 1.1 (0.6 to 1.8), p = 0.828 3.4 (0.9 to 13.1), p = 0.078 3.4 (0.8 to 13.5), p = 0.085
CRP >100 1.2 (0.7 to 2.2), p = 0.477 1.2 (0.7 to 2.3), p = 0.514 6.4 (0.7 to 54.8), p = 0.091 4.5 (0.5 to 40.9), p = 0.18
PCT (μg/L) 1.1 (0.6 to 1.7), p = 0.845 1.0 (0.6 to 1.7), p = 0.939 0.9 (0.4 to 1.9), p = 0.804 0.8 (0.4 to 1.7), p = 0.588
PCT ≤0.1 Reference group Reference group Reference group Reference group
PCT 0.1-0.25 0.8 (0.5 to 1.3), p = 0.439 0.8 (0.5 to 1.3), p = 0.466 1.1 (0.7 to 1.9), p = 0.655 1.1 (0.6 to 1.9), p = 0.738
PCT 0.25-0.5 3.3 (0.6 to 18.0), p = 0.166 2.9 (0.5 to 16.3), p = 0.229 2.5 (0.2 to 28.5), p = 0.460 1.8 (0.2 to 21.4), p = 0.63
PCT >0.5 1.6 (0.5 to 4.7), p = 0.402 1.5 (0.5 to 4.5), p = 0.486 0.5 (0.0 to 5.7), p = 0.540 0.3 (0.0 to 4.6), p = 0.42














Interestingly, as shown in our correlation analyses, pa-
tients displayed differences in biomarker profiles with
low correlation between markers and between cut-off
ranges. Because both markers had suboptimal prognos-
tic accuracy for outcome prediction, and because no
goldstandard for ARI in need of antibiotics exist, only a
head to head trial comparing the performance of both
markers in regard to antibiotic management may help
to clarify the question which marker is more helpful in
the management of ARI patients.
Several limitations should be considered when inter-
preting our results. First, this is a secondary analysis of
previous randomized study with a different study ques-
tion, i.e., whether antibiotic therapy guided by PCT re-
duces the use of antibiotics without increasing the
restrictions experienced by patients. Second, no external
validation of ARI diagnoses was done. Instead, physi-
cians were encouraged to use updated guidelines pre-
sented in an interactive seminar. Also, chest X-ray was
not mandatory for diagnosis of CAP and some patients
may have been misclassified. In addition, we classified
patients with common cold, influenza, and acute
laryngitis-bronchitis as lower ARI because they fre-
quently presented with cough as a main symptom and
pathological findings in chest auscultation. Third, we fo-
cused on adverse outcomes as specified in the original
trials but did not look into other adverse outcomes such
as unplanned readmission to the GP, hospital admission,
and respiratory failure among others. Further, PCT was
not measured on site, due to lack of sensitive POC at
that time. Future studies comparing these markers
should also look into POC system for both markers in
primary care.
Conclusion
This is the first large and comprehensive study investi-
gating correlations between CRP and PCT and their pre-
dictive value in the primary care setting in patients with
different types of ARI. The low correlations between the
two biomarkers and the only moderate prognostic accur-
acy calls for a head-to-head trial comparing the ability of
both markers to manage primary care patients with ARI
to answer the question which marker is superior.
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